Fred Alger Management, LLC Alkermes Plc. Transaction History

Fred Alger Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$28.34 - $33.63 $52,003 - $61,711	-1,835 Reduced 2.38%	75,413 $2.36 Million
Q1 2023 May 15, 2023	BUY	$25.31 - $29.02 $379 - $435	15 Added 0.02%	77,248 $2.18 Million
Q4 2022 Feb 14, 2023	SELL	$21.94 - $26.24 $26.1 Million - $31.2 Million	-1,187,771 Reduced 93.89%	77,233 $2.02 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $3.42 Million - $4.95 Million	155,299 Added 13.99%	1,265,004 $28.2 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $26.3 Million - $30.4 Million	995,026 Added 867.66%	1,109,705 $33.1 Million
Q1 2022 May 16, 2022	BUY	$23.07 - $27.99 $2.65 Million - $3.21 Million	114,679 New	114,679 $3.02 Million
Q4 2017 Feb 14, 2018	SELL	$47.69 - $55.39 $691,505 - $803,155	-14,500 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$49.16 - $54.45 $712,820 - $789,525	14,500	14,500 $737,000

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.73B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.